drugset
Drugs / DZD6008
last change May 2026 re-read 8 days ago

DZD6008

targets EGFR via inhibition

Developed for
non-small cell lung carcinoma
Investigated by
Dizal Pharmaceuticals

Trials 4

today NCT07079475 · Ph 1/2 NCT07070440 · Ph 1/2 NCT06905197 · Ph 1 NCT06813365 · Ph 1
2025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT06905197 May 2025 → Sep 2027 expected non-small cell lung carcinoma Dizal Pharmaceuticals Recruiting No outcome recorded
Phase 1 NCT06813365 Jun 2024 → Dec 2026 expected non-small cell lung carcinoma Dizal Pharmaceuticals Recruiting No outcome recorded
Phase 1/22 trials
Phase 1/2 NCT07079475 Jul 2025 → Jun 2028 expected non-small cell lung carcinoma Dizal Pharmaceuticals Recruiting No outcome recorded
Phase 1/2 NCT07070440 Jul 2025 → Jun 2027 expected non-small cell lung carcinoma Dizal Pharmaceuticals Recruiting No outcome recorded

News releases announcing trial results or a regulatory action · 1

DateIssuerRelease
2026-05-31 Dizal Pharmaceuticals Results Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-1 at ASCO 2026 dizalpharma.com ↗
The latest findings showed that DZD6008 demonstrated strong and durable anti-tumor activity in patients relapsed from third-generation EGFR TKI with a favorable safety profile.

All press releases naming this drug 2 releases

DateIssuerRelease

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as DZD6008 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06813365 ↗
3

NCT06905197 ↗

NCT07070440 ↗

NCT07079475 ↗
Action Inhibit “Oral EGFR Inhibitor” NCT06813365 ↗
Route Oral “Oral EGFR Inhibitor” NCT06813365 ↗
Target EGFR “Oral EGFR Inhibitor” NCT06813365 ↗